The integration of real-world data into clinical research may mark a shift away from clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.
The integration of real-world data into clinical research may mark a shift away from clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.
Transcript
How has a growing understanding and acceptance of real-world data led to it being used more in clinical research?
When you think about the real world data movement, in the beginning of it, it really happened 5 or 6 years ago with the Affordable Care Act, where there was EMR adoption and it was forced on providers. You see this huge spike from, basically EMR adoption in the tens to the eighties in about 5 or 6 years. All this information, which used to be in a black box, is now digitized. The second main milestone was the Affordable Care Act, which essentially mandated for the first time that the federal government would consider alternatives to traditional clinical trial information, ie, real-world data. Since then, what is really driving adoption in consideration of real-world data is validation work, cross-industry validation work. So, I think about the last year and think about the Friends of Cancer research efforts that have that have come a long way. I think about Duke Margolis, and a lot of these policy stakeholders that are working with industry partners, with data companies, and sponsors, to define what are real world data endpoints. How do we consider this information in lieu of clinical trial information? Of course, the best way to advance the movement is examples. Probably the most exciting example this year was Pfizer's Ibrance being approved with no clinical trial information at all, exclusively using real world data. So, I think what we're going to see moving forward is continued applications and adoptions like Pfizer Ibrance as well as additional methodology work.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More